Novo Nordisk Stock Rises 2.7% After CagriSema Trial Data
Why is Novo Nordisk stock up today?
Novo Nordisk (NOVO-B.CO) stock rose 2.7% to 286.1 kroner on Monday after trial data showed its CagriSema obesity drug cut weight by about 21%, with a US decision due this quarter.
Key numbers
| Weight loss, 1.0 mg dose | 21.0%vs 2.0% placebo |
|---|---|
| Weight loss, 1.7 mg dose | 20.7%vs 2.0% placebo |
| Novo shares, Copenhagen | 286.1 DKK+2.7% |
| Novo shares, US (NVO) | NYSE+2.4% |
| Quit due to side effects | 2.9%–4.9%vs 4.9% placebo |
What happened
Novo Nordisk (NOVO-B.CO) stock rose 2.7% to 286.1 kroner on Monday after trial data showed its CagriSema obesity drug cut weight by about 21%, with a US decision due this quarter. In a 68-week study of 309 adults, the two lower doses led to average weight loss of 20.7% and 21.0%, compared with 2.0% for people given a dummy shot (placebo). Those figures assume patients stayed on treatment. The company's US-listed shares (NVO) rose about 2.4%.
Why it matters
Novo Nordisk needs a strong next-generation weight-loss drug to keep up with Eli Lilly, which has already launched its own obesity pill and just raised its sales forecast. CagriSema combines two medicines that mimic natural appetite-control hormones, and about 21% weight loss is near the top of what drugs in this class have shown. The US decision is expected in the fourth quarter, but that timing is the company's own expectation, not an FDA promise.
Who this affects
- MarketbullishLow impact
- Novo shareholders gained modestly; wider market barely moved.
- CompanybullishMedium impact
- Strong data supports Novo's case for US approval.
- CompetitorsbearishLow impact
- Eli Lilly faces a tougher rival if CagriSema is approved.
- IndustrybullishMedium impact
- Obesity drug makers see more choice and competition for patients.
Novo Nordisk vs Eli Lilly, Pfizer, Amgen
How we got here
Novo Nordisk files its US application for CagriSema in obesity.
REDEFINE 9 results presented at ObesityWeek and published in The Lancet Diabetes & Endocrinology.
Novo shares rise 2.7% in Copenhagen; US shares up about 2.4%.
What to watch
- US FDA decision on CagriSema for obesity, expected by Novo in the fourth quarter.Q4 2026
- Stomach side effects, reported in 79.6% of CagriSema users versus 39.9% on placebo in an earlier trial.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →

Intel Stock Falls 6% After Shareholder Class Action
Intel (INTC) trades near $56, about 39% below its Oct. 29 close, as investors sue over PC-sales weakness.
Take-Two Stock Rises 3% Ahead of GTA VI Launch
Take-Two (TTWO) gains as Jefferies keeps its $300 target ahead of Thursday's GTA VI launch.

Tyson Foods Stock Jumps 9% After Earnings Beat
Tyson Foods (TSN) earned $0.61 a share and guided to a much smaller beef loss in fiscal 2027.